These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 36341437)
1. The role of cuproptosis-related gene in the classification and prognosis of melanoma. Liu JY; Liu LP; Li Z; Luo YW; Liang F Front Immunol; 2022; 13():986214. PubMed ID: 36341437 [TBL] [Abstract][Full Text] [Related]
2. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X Front Immunol; 2022; 13():1056932. PubMed ID: 36479114 [TBL] [Abstract][Full Text] [Related]
3. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma. Chen X; Hu G; Xiong L; Xu Q Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162 [No Abstract] [Full Text] [Related]
4. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma. Wang J; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Qin D; Zhong S; Hu X Front Oncol; 2023; 13():1152681. PubMed ID: 37333810 [TBL] [Abstract][Full Text] [Related]
5. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201 [TBL] [Abstract][Full Text] [Related]
6. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma. Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226 [TBL] [Abstract][Full Text] [Related]
7. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. Yan C; Niu Y; Ma L; Tian L; Ma J J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876 [TBL] [Abstract][Full Text] [Related]
8. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma. Zhang Y; Zhou J; Li H; Liu Y; Li J BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925 [TBL] [Abstract][Full Text] [Related]
9. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma. Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R Front Immunol; 2022; 13():990790. PubMed ID: 36248822 [TBL] [Abstract][Full Text] [Related]
10. Identification of cuproptosis-related subtypes and development of a prognostic signature in colorectal cancer. Huang Y; Yin D; Wu L Sci Rep; 2022 Oct; 12(1):17348. PubMed ID: 36253436 [TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a cuproptosis-related prognostic model for glioblastoma. Zhang B; Xie L; Liu J; Liu A; He M Front Immunol; 2023; 14():1082974. PubMed ID: 36814929 [TBL] [Abstract][Full Text] [Related]
12. A novel cuproptosis-related prognostic gene signature in adrenocortical carcinoma. Gao W; He X; Huangfu Q; Xie Y; Chen K; Sun C; Wei J; Wang B J Clin Lab Anal; 2023 Nov; 37(21-22):e24981. PubMed ID: 37997497 [TBL] [Abstract][Full Text] [Related]
13. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma. Li J; Yin J; Li W; Wang H; Ni B Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100 [TBL] [Abstract][Full Text] [Related]
14. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA. Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P Front Immunol; 2022; 13():919231. PubMed ID: 35967366 [TBL] [Abstract][Full Text] [Related]
15. Construction of a novel cuproptosis-related gene signature for predicting prognosis and estimating tumor immune microenvironment status in papillary thyroid carcinoma. Wang L; Yao B; Yang J; Tian Z; He J BMC Cancer; 2022 Nov; 22(1):1131. PubMed ID: 36333684 [TBL] [Abstract][Full Text] [Related]
16. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas. Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP Front Immunol; 2022; 13():933973. PubMed ID: 36045691 [TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma. He F; Zeng P; Ma S; Yang X; Liu H; Liu Q; Zhou Y; Zhu H Front Pharmacol; 2023; 14():1088993. PubMed ID: 36843949 [No Abstract] [Full Text] [Related]
18. Characterization of a cuproptosis-related signature to evaluate immune features and predict prognosis in colorectal cancer. Li L; Sun F; Kong F; Feng Y; Song Y; Du Y; Liu F; Kong X Front Oncol; 2023; 13():1083956. PubMed ID: 37384293 [TBL] [Abstract][Full Text] [Related]
19. Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma. Liu D; Yang F; Zhang T; Mao R J Transl Med; 2023 Jan; 21(1):57. PubMed ID: 36717900 [TBL] [Abstract][Full Text] [Related]
20. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma. Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P Front Immunol; 2022; 13():998236. PubMed ID: 36110851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]